Spruce Biosciences, Inc.

SPRB

Healthcare Biotechnology

Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.

Revenue
−75.9%
EPS
−90.9%
Free cash flow
−152.1%
Total debt
+427.2%

Quarter to June 2026, against a year earlier

46.55 3.84 +8.99%
Market cap
$133.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.3×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Total current assets
52.11 44.21 102.18 83.61 91.90 160.40 4.65 4.77
Total non-current assets
0.91 1.00 1.76 2.04 34.59 2.49 0.04 —
Total Assets
53.02 45.21 103.95 85.65 126.49 162.88 4.69 4.78
Total current liabilities
10.09 15.25 24.47 12.45 8.87 9.76 4.30 2.71
Total non-current liabilities
0.42 1.14 2.97 4.72 6.24 3.69 3.21 —
Total liabilities
10.51 16.39 27.44 17.16 15.12 13.46 7.52 2.71
Common Equity (Total)
42.52 28.82 76.51 68.49 111.37 149.43 (30.64) (17.80)
Shareholders Equity (Total)
42.52 28.82 76.51 68.49 111.37 149.43 (2.82) 2.07
Total Debt
— 1.75 3.34 4.92 5.24 4.48 4.45 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026